Redhill Biopharma Ltd. - American Depositary Shares (RDHL)
5.5900
0.00 (0.00%)
Redhill Biopharma is a biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and other serious conditions
The company specializes in creating novel formulations and repurposing existing drugs to improve treatment outcomes for patients. Redhill is dedicated to addressing unmet medical needs through its robust pipeline of products, which includes both clinical-stage candidates and marketed drugs. By leveraging advanced scientific research and a strategic approach to drug development, Redhill aims to improve the lives of patients suffering from complex health issues.
![](https://public.newsdirect.com/769476017/99Dg9VNy.png)
New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance
Via News Direct · February 5, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 21, 2025
![](https://public.newsdirect.com/834870638/Jojotw4q.png)
Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit
Via News Direct · December 9, 2024
![](https://public.newsdirect.com/746756154/C0wTwKQs.png)
RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment
Via News Direct · October 15, 2024
![](https://investorplace.com/wp-content/uploads/2023/11/rdhl1600.png)
One of today's biggest market movers in the biotech space is RedHill Biuopharma, with RDHL stock up more than 75% on big news.
Via InvestorPlace · August 1, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 3, 2024
![](https://public.newsdirect.com/700790890/CeK1cfK9.png)
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
Via News Direct · August 23, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/19/RDHL.png?width=1200&height=800&fit=crop)
RedHill Biopharma released study results showing opaganib's potential in treating Type 2 diabetes and obesity. The drug's ability to target sphingolipid metabolism could help prevent weight gain and improve glucose tolerance.
Via Benzinga · August 19, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/01/wall-street-chart-shutter2_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 1, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 18, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 1, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/25/image19.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also rose, gaining, 0.19% to 4,877.88.
Via Benzinga · January 25, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/25/humana_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of Humana Inc. (NYSEHUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via Benzinga · January 25, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/25/image48.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&P 500 also rose, gaining, 0.26% to 4,881.28.
Via Benzinga · January 25, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 25, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/25/image20.jpeg?width=1200&height=800&fit=crop)
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.33% to 37,932.33 while the NASDAQ rose 0.37% to 15,538.69. The S&P 500 also rose, gaining, 0.40% to 4,887.88.
Via Benzinga · January 25, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/24/image_2.jpg?width=1200&height=800&fit=crop)
Shares of BlackBerry Limited (NYSEBB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
Via Benzinga · January 24, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 24, 2024
![](https://cdn.benzinga.com/files/images/story/2024/medicine-1905067-1280.jpeg?width=1200&height=800&fit=crop)
Redhill Biopharma Ltd. shares are trading higher Wednesday after the company was granted a patent for a method for eradicating helicobacter pylori infections in patients regardless of body mass index.
Via Benzinga · January 24, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/24/image16.jpg?width=1200&height=800&fit=crop)
Shares of Netflix, Inc. (NASDAQNFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-expected sal
Via Benzinga · January 24, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 24, 2024
![](https://investorplace.com/wp-content/uploads/2021/05/wall-street-morning.jpg)
It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.
Via InvestorPlace · January 24, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 23, 2024